Skip to main content

Table 2 Comparison of Fibroadenomas size changes in the two groups

From: Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial

 

Metformin Group

Placebo Group

p-value

Average of largest mass size before intervention (mm)

13.06 ± 4.46

13.52 ± 5.96

0.57

Average of largest mass size after intervention (mm)

10.66 ± 6.49

11.48 ± 8.11

0.47

Change in size of the largest mass (mm)

2.40 ± 4.96

2.04 ± 6.67

0.69

Average of smallest mass size before intervention (mm)

6.81 ± 2.25

7.65 ± 3.36

0.19

Average of smallest mass size after intervention (mm)

3.58 ± 4.21

7.51 ± 7.38

0.006

Change in size of the smallest mass (mm)

3.26 ± 3.26

0.14 ± 6.48

0.007

 A less than 20 % increase of largest mass, n (%)

74 (94 %)

81 (88 %)

 

A more than 20 % increase of largest mass, n (%)

5 (6 %)

11 (12 %)

0.17

 A less than 20 % increase of smallest mass, n (%)

41 (95.3 %)

27 (75 %)

 

A more than 20 % increase of smallest mass, n (%)

2 (4.7 %)

9 (25 %)

0.009

  1. P-value refers to Chi-square and Student T-test, when appropriate